Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer

BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer

Bristol Myers Squibb (BMS) has shared positive results from a late stage study of Opdivo (nivolumab) plus Yervoy (ipilimumab) in a subset of colorectal cancer patients. ... Opdivo plus Yervoy-based combinations already hold approvals for a range of

Bristol Myers Squibb's lung cancer drug Augtyro receives FDA approval

Bristol Myers Squibb's lung cancer drug Augtyro receives FDA approval The FDA’s decision on Augtyro comes just one month after BMS received approval from the US regulator for its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in adults and adolescents ... Opdivo, which utilises the body’s own immune system to help

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer trial

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer trial Bristol Myers Squibb (BMS) has shared positive results from a late-stage study of a new injectable form of Opdivo (nivolumab) in certain kidney cancer patients. ... Subcutaneous Opdivo met its co-primary pharmacokinetics endpoints and also demonstrated a

Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use

Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use Opdivo is a PD-1 immune checkpoint inhibitor that is designed to utilise the body’s own immune system to help restore an anti-tumour immune response. ... Opdivo is currently approved in more than 65 countries, including the US, EU, Japan and China, for

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials The announcement comes just days after BMS shared six-year follow-up results  from a late-stage study of Opdivo (nivolumab) plus Yervoy (ipilimumab) in certain lung cancer patients.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...